Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 8 Results

  1. 1
    373618

    [New recommendations from the World Health Organization (WHO) for the use of contraceptive methods] Nuevas recomendaciones de la Organizacion Mundial de la Salud (OMS) para el uso de los metodos anticonceptivos.

    Cravioto MD

    Gaceta Medica De Mexico. 2016 Sep - Oct; 152(5):601-603.

    The Medical Eligibility Criteria for Contraceptive Use of the World Health Organization have been updated recently. These criteria constitute a guideline for the selection of family planning methods appropriated for women and men with known medical conditions or personal characteristics of medical relevance. The guidelines last updating incorporates recommendations for the use of a new emergency contraceptive pill and three long-acting hormonal methods, and revises some previously established recommendations. This article provides information on the last edition of such document and aims to contribute to its dissemination.
    Add to my documents.
  2. 2
    312831

    Levonorgestrel alone for emergency contraception.

    Contraception Report. 1999 Jan; 9(6):[4] p..

    A recent WHO-sponsored study has demonstrated that the progestin levonorgestrel, used alone, is a highly effective and well-tolerated form of emergency contraception. With the proportion of pregnancies prevented up to 95% - depending on the timeliness of administration - the levonorgestrel regimen proved more effective than the most commonly used regimen, the Yuzpe method. The Yuzpe method employs a dual-hormone (ethinyl estradiol plus levonorgestrel) approach to preventing pregnancy. Despite the Yuzpe regimen's 75% efficacy rate (a weighted average from 10 studies) the method has been associated with drawbacks. About 50% of users experience nausea and 20% report vomiting, which can reduce patient compliance. (excerpt)
    Add to my documents.
  3. 3
    286564

    Reproductive health conference urges wider use emergency contraception.

    World Health Organization [WHO]. Special Programme of Research, Development and Research Training in Human Reproduction

    Progress in Reproductive Health Research. 1995; (35):8.

    Emergency contraception should be available to all women who wish to use it, according to a recent conference of reproductive health specialists. In a consensus statement the group asserted that “millions of unwanted pregnancies could be averted” if emergency contraceptives were widely accessible. The conference called for further research on antiprogestogens for emergency contraceptive use. Emergency contraceptives are methods that women use after intercourse to prevent pregnancy. Several methods are known to be safe and effective, including higher doses of regular combined ethinyl estradiol/levonorgestrel contraceptives (the Yuzpe regimen) and the copper intrauterine device (IUD). Levonorgestrel may also be used, and mifepristone (an antiprogesterone drug that supresses ovulation and can inhibit implantation of the fertilized ovum in the uterus wall) is currently being studied to ascertain the optimal dose. “Any woman at risk of unwanted pregnancy may need these methods occasionally,” conference delegates agreed. (excerpt)
    Add to my documents.
  4. 4
    276281
    Peer Reviewed

    Contemporary issues in women's health.

    Arulkumaran S; Johnson TR

    International Journal of Gynecology and Obstetrics. 2004 Nov; 87(2):111-113.

    In May 2004, the Food and Drug Administration of the United States ruled that emergency contraception would not be available over the counter. In December 2003, two FDA expert panels overwhelmingly recommended approval of the drug by a 23 to 4 vote after reviewing more than 15,000 pages of data for over 40 studies in support of the over the counter (OTC) application. The FDA typically follows the recommendations of the government scientific committees, and the experts in this case made it clear that use of emergency contraception does not increase promiscuity or unprotected sex among teenaged women. In an unusual decision written by Dr. Steven Galson, Acting Director of FDA’s Center for Drug Evaluation and Research, and not supported by other members of the FDA staff, a decision was deferred pending further information about the safety of emergency contraception in girls under the age of 16 or on the possibility raised by the manufacturer in their proposal that the drug be used over the counter for girls over the age of 16 and that there be an age limit to those who could get it without speaking to a pharmacist or without a prescription. (excerpt)
    Add to my documents.
  5. 5
    189803
    Peer Reviewed

    Meta-analyses of randomized trials comparing different doses of mifepristone in emergency contraception.

    Piaggio G; von Hertzen H; Heng Z; Xiao B; Cheng L

    Contraception. 2003 Dec; 68(6):447-452.

    There is some evidence from randomized trials that different doses of mifepristone for emergency contraception do not differ in efficacy in the range from 10 mg to 600 mg. Lower doses have a better side effect profile and are cheaper and therefore they would be preferable in the absence of a dose effect. However, the lack of significance is not evidence of absence of an effect. More evidence can be obtained by combining results of trials. We present meta-analyses of randomized trials comparing doses of mifepristone for emergency contraception from 5 mg to 600 mg, with regard to the efficacy to prevent unwanted pregnancies. We use two approaches for analysis, one using only within-trial information and another one combining within-trial with between-trial information. We discuss the results in terms of equivalence. There is some evidence of a small dose effect on efficacy in the lower range of doses (<50 mg). The pregnancy rate increases by a factor of 1.6 when the dose of 10 mg is used instead of 25 mg (95% confidence interval: 1.1–2.4). In terms of the number of women needed to treat, however, using 10 mg in the place of 25 mg implies having one extra pregnancy every 146 women requesting emergency contraception, which might be a low cost compared to the benefit of more women having access to treatment. (author's)
    Add to my documents.
  6. 6
    189802
    Peer Reviewed

    Combined estimates of effectiveness of mifepristone 10 mg in emergency contraception.

    Piaggio G; Heng Z; von Hertzen H; Xiao B; Cheng L

    Contraception. 2003 Dec; 68(6):439-446.

    The present paper combines the estimates of efficacy and side effects of 10 mg mifepristone for emergency contraception obtained from randomized trials. A total of 6083 women participating in 12 randomized trials and receiving 10 mg mifepristone for emergency contraception up to 120 h after intercourse, were analyzed for efficacy. Between 4188 and 5833 women were analyzed for side effects and 3601 for delay of menses of more than 7 days. Prevented fractions, the effect of delay and of further acts of intercourse after treatment administration were analyzed in 3440 women, using individual data. The combined pregnancy rate from all the 12 trials was 1.7% [101/6083, 95% confidence interval (CI): 1.3–2.2]. From the three trials providing individual data, the combined pregnancy rate was 1.3% (45/3440, 95% CI: 0.9 –1.7) and the estimate of pregnancies prevented was 83.4% (95% CI: 77.4–87.8). There was a sharp decline in efficacy when treatment was administered during the 5th day after intercourse compared to administration during the 1st day, the odds of pregnancy increasing by a factor of 5.3 (95% CI: 1.9 –14.9). The relative risk of pregnancy was about 28 times higher among women with unprotected acts of coitus between treatment administration and the onset of next menses, compared with women reporting none [odds ratio (OR) = 27.6, 95% CI: 12.7– 60.2]. The increase in risk for women reporting protected acts of intercourse during this interval was not statistically significant (OR = 1.8, 95% CI: 0.9 –3.8). There was a large heterogeneity among trials in all side effects and delay of menses of more than 7 days (all had p < 0.0001 for the test of homogeneity). The percentage of women with nausea ranged from 0.0–19.4% (highest upper 95% confidence limit: 23.0%), that of vomiting from 0.0–4.3% (highest upper 95% confidence limit: 6.1%), that of lower abdominal pain from 4.3–19.1% (highest upper 95% confidence limit: 22.7%). The percentage of women with delay of menses of more than 7 days ranged from 4.3–25.8% (highest upper 95% confidence limit: 34.1%). We conclude that 10 mg mifepristone is an effective emergency contraception regimen, with an acceptable side-effects profile. Postponing treatment until the 5th day seriously decreases efficacy. The risk of pregnancy is dramatically increased among women having unprotected acts of intercourse between treatment administration and the onset of next menses. This risk may be enhanced for women whose ovulation is postponed by treatment. (author's)
    Add to my documents.
  7. 7
    189764
    Peer Reviewed

    Summary of evidence and research needs on the use of mifepristone in fertility regulation: consensus from the conference.

    Conference on the Use of Mifepristone to Reduce Unwanted Pregnancy (2001: Bellagio)

    Contraception. 2003 Dec; 68(6):401-407.

    The conference on the use of mifepristone to reduce unwanted pregnancy, sponsored by the World Health Organization, Concept Foundation and the Rockefeller Foundation, took place in Bellagio, Italy, between 24 and 28 September 2001. The objective of the conference was to review the scientific information and to evaluate the use of mifepristone for emergency contraception, luteal contraception and menstrual induction. Mifepristone is highly effective for emergency contraception but its advantages and disadvantages in comparison with levonorgestrel need to be further studied. Data indicate that mifepristone alone or in combination with misoprostol has potential for occasional use for women seeking help following repeated unprotected intercourse and/or when the interval between intercourse and treatment is more then 120 h. Administration of mifepristone immediately after ovulation seems to be an effective contraceptive method. However, before it can be used commonly, there is a need for a simple and inexpensive method to identify the right time in the cycle. Once-a-month treatment with mifepristone and misoprostol at the expected time of menstruation is not a practical method due to bleeding irregularities and timing of treatment. Menstrual induction with mifepristone and a suitable prostaglandin analogue is highly effective. A randomized comparison with manual vacuum aspiration is, however, needed before it can be recommended for routine use. (author's)
    Add to my documents.
  8. 8
    176643
    Peer Reviewed

    Policy climate, scholarship, and provision of emergency contraception at affiliates of the International Planned Parenthood Federation in Latin America and the Caribbean.

    Diaz-Olavarrieta C; Turner AN; Ellertson C; Helzner JF; Ezcurra E

    Contraception. 2002 Feb; 65(2):143-149.

    Emergency contraception (EC) has great potential to decrease the incidence and resulting consequences of unwanted pregnancy, including unsafe abortion. We conducted this study to understand EC practices in Latin America and the Caribbean (LAC). We contacted 43 International Planned Parenthood Federation affiliates in LAC to interview them about EC availability. We collected family planning norms and researched registered EC products in LAC. We searched English- and Spanish-language sources to compile EC literature reviews. Thirty-seven affiliates (86%) responded to the survey, and 62% offer EC. Central and South American affiliates are more likely to offer EC than are Caribbean affiliates. Of those offering EC, 96% offer cut-up packets of oral contraceptives, whereas six affiliates offer dedicated products. Of those not offering EC, 79% believe it constitutes abortion. EC availability and support for the method appear to be increasing in LAC, and clearer distinctions between EC and abortion in medical and policy guidelines should increase acceptance further. (author's)
    Add to my documents.